Naltrexone for Nonsuicidal Self-Injury

This randomized, double-blinded, placebo-controlled clinical trial aims to evaluate the efficacy and safety of naltrexone in reducing nonsuicidal self-injurious behavior among individuals with nonsuicidal self-injury. Participants will be randomly assigned to receive either naltrexone plus treatment as usual or placebo plus treatment as usual for 6 weeks. The primary objective is to determine whether naltrexone reduces the frequency of nonsuicidal self-injurious behavior compared with placebo. Secondary objectives include evaluating changes in clinical severity, suicidal ideation, self-injury-related urges, ecological momentary assessment measures, and safety outcomes.

NCT Number	NCT07641283
Lead Sponsor	Seoul National University Hospital Collaborators: Asan Medical Center, Uijeongbu Eulji University Hospital
Conditions	Nonsuicidal Self-Injury, Self-Injurious Behavior
Enrollment	150 participants
Start Date	2026-06
Primary Completion	2027-12 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-11